| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89d397e2fff9dece10c981cc12cb9f06 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08J2305-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2400-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08J3-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-52 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08J3-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08L5-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-728
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 |
| filingDate |
2018-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a79ae26ff88867960b26f511d3ec8f17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35468dd81d69d6969bacad7c20ea0361 |
| publicationDate |
2020-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-111315813-A |
| titleOfInvention |
Absorbable implantable devices based on cross-linked glycosaminoglycans and methods of making the same |
| abstract |
Disclosed is a method for preparing a hydrogel composed of cross-linked glycosaminoglycans, the method comprising: a) making at least one hydrogel obtained by heating aqueous solutions of low molecular weight and high molecular weight glycosaminoglycans at 80-160° C. The hybrid cooperative complex is reacted with a diepoxide as a crosslinking agent in a ratio of 0.1 to 1 equivalent, preferably 0.2 to 0.4 equivalent to the complex, the weight concentration of the complex in solution being in the range of 1 % to 15%, preferably 2% to 10%; b) Purification by dialysis, ultrafiltration and diafiltration. |
| priorityDate |
2017-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |